Joost’s scientific publications

  1. Type I CD20 antibodies recruit the B-cell receptor for complement-dependent lysis of malignant B cells. Patrick J. Engelberts, Marleen Voorhorst, Janine Schuurman, Tom van Meerten, Joost M. Bakker, Tom Vink, Wendy J. M. Mackus, Esther C.W. Breij, Stefanie Derer, Thomas Valerius, Jan G.J. van de Winkel, Paul W.H.I Parren, Frank J. Beurskens. J. Immunol. 2016. Published November 2, 2016, doi:10.4049/jimmunol.1600811.
  2. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar RA, Bakker JM, Lammerts-van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, Martens A, Mutis T. Clin Cancer Res. 2014 Nov 14. pii: clincanres.1813.2014. [Epub ahead of print]
  3. Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity. Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren, and Ronald P. Taylor. Handbook of Therapeutic Antibodies (2014), S. Dübel, J. M. Reichert eds.
  4. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PWHI, Lokhorst HM and Mutis T. Blood Cancer J. (2011) 1, e41. Published online 28 October 2011.
  5. Complement activation by (auto-) antibodies. Daha NA, Banda NK, Roos A, Beurskens FJ, Bakker JM, Daha MR, Trouw LA.Mol Immunol. 2011 Aug;48(14):1656-65.
  6. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. Haematologica. 2011 Feb;96(2):284-90.
  7. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. J Immunol. 2011 Feb 1;186(3):1840-8.
  8. Fc receptor but not complement binding is important in antibody protection against HIV. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. Nature. 2007 Sep 6;449(7158):101-4.
  9. Reduced life expectancy in rats after neonatal dexamethasone treatment. Kamphuis PJ, de Vries WB, Bakker JM, Kavelaars A, van Dijk JE, Schipper ME, van Oosterhout MF, Croiset G, Heijnen CJ, van Bel F, Wiegant VM. Pediatr Res. 2007 Jan;61(1):72-6.
  10. Therapeutic antibody gene transfer: an active approach to passive immunity. Bakker JM, Bleeker WK, Parren PW. Mol Ther.2004 Sep;10(3):411-6. Review.
  11. Neonatal dexamethasone treatment affects social behaviour of rats in later life. Kamphuis PJ, Croiset G, Bakker JM, Van Bel F, Van Ree JM, Wiegant VM. Neuropharmacology. 2004 Sep;47(3):461-74.
  12. Long-lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity: involvement of the NMDA receptor complex. Kamphuis PJ, Gardoni F, Kamal A, Croiset G, Bakker JM, Cattabeni F, Gispen WH, van Bel F, Di Luca M, Wiegant VM. FASEB J. 2003 May;17(8):911-3.
  13. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, Bakker JM, Wiegant VM, Heijnen CJ, Veen S, van Bel F. Acta Paediatr. 2003 Jul;92(7):827-35.
  14. Maternal deprivation of rat pups increases clinical symptoms of experimental autoimmune encephalomyelitis at adult age.
    Teunis MA, Heijnen CJ, Sluyter F, Bakker JM, Van Dam AM, Hof M, Cools AR, Kavelaars A. J Neuroimmunol. 2002 Dec;133(1-2):30-8.
  15. Alterations in adult rat heart after neonatal dexamethasone therapy. de Vries WB, van der Leij FR, Bakker JM, Kamphuis PJ, van Oosterhout MF, Schipper ME, Smid GB, Bartelds B, van Bel F. Pediatr Res. 2002 Dec;52(6):900-6.
  16. Enhanced glucocorticoid feedback inhibition of hypothalamo-pituitary-adrenal responses to stress in adult rats neonatally treated with dexamethasone. Kamphuis PJ, Bakker JM, Broekhoven MH, Kunne C, Croiset G, Lentjes EG, Tilders FJ, van Bel F, Wiegant VM. Neuroendocrinology. 2002 Sep;76(3):158-69.
  17. Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. Teunis MA, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, Heijnen CJ. FASEB J. 2002 Sep;16(11):1465-7.
  18. Neonatal glucocorticoids and the developing brain: short-term treatment with life-long consequences?
    Bakker JM, van Bel F, Heijnen CJ. Trends Neurosci. 2001 Nov;24(11):649-53. Review.
  19. Neonatal dexamethasone treatment induces long-lasting changes in T-cell receptor vbeta repertoire in rats. Bakker JM, Kavelaars A, Kamphuis PJ, Zijlstra J, van Bel F, Heijnen CJ. J Neuroimmunol. 2001 Jan 1;112(1-2):47-54.
  20. Neonatal dexamethasone treatment increases susceptibility to experimental autoimmune disease in adult rats. Bakker JM, Kavelaars A, Kamphuis PJ, Cobelens PM, van Vugt HH, van Bel F, Heijnen CJ. J Immunol. 2000 Nov 15;165(10):5932-7.
  21. Altered immune function in human newborns after prenatal administration of betamethasone: enhanced natural killer cell activity and decreased T cell proliferation in cord blood. Kavelaars A, van der Pompe G, Bakker JM, van Hasselt PM, Cats B, Visser GH, Heijnen CJ. Pediatr Res. 1999 Mar;45(3):306-12.
  22. Functional immaturity of rat alveolar macrophages during postnatal development. Bakker JM, Broug-Holub E, Kroes H, van Rees EP, Kraal G, van Iwaarden JF. Immunology. 1998 Jul;94(3):304-9.
  23. The steroid hormone dehydroepiandrosterone (DHEA) breaks intranasally induced tolerance, when administered at time of systemic immunization. Wolvers DA, Bakker JM, Bagchus WM, Kraal G. J Neuroimmunol. 1998 Aug 14;89(1-2):19-25.
  24. Long-term gender-specific effects of manipulation during pregnancy on immune and endocrine responsiveness in rat offspring. Bakker JM, van den Dobbelsteen GP, Kroes H, Kavelaars A, Heijnen CJ, Tilders FJ, van Rees EP. J Neuroimmunol.1998 Feb;82(1):56-63.
  25. Effects of neonatal dexamethasone treatment on hypothalamo-pituitary adrenal axis and immune system of the rat.
    Bakker JM, Schmidt ED, Kroes H, Kavelaars A, Heijnen CJ, Tilders FJ, van Rees EP. J Neuroimmunol. 1997 Apr;74(1-2):69-76.
  26. Ontogency of the responses of human peripheral blood T cells to glucocorticoids. Kavelaars A, Cats B, Visser GH, Zegers BJ,Bakker JM, van Rees EP, Heunen CJ. Brain Behav Immun. 1996 Sep;10(3):288-97.
  27. Effects of short-term dexamethasone treatment during pregnancy on the development of the immune system and the hypothalamo-pituitary adrenal axis in the rat. Bakker JM, Schmidt ED, Kroes H, Kavelaars A, Heijnen CJ, Tilders FJ, van Rees EP. J Neuroimmunol. 1995 Dec 31;63(2):183-91.
  28. Increased dexamethasone sensitivity of neonatal leukocytes: different mechanisms of glucocorticoid inhibition of T cell proliferation in adult and neonatal cells. Kavelaars A, Zijlstra J, Bakker JM, Van Rees EP, Visser GH, Zegers BJ, Heijnen CJ.
    Eur J Immunol. 1995 May;25(5):1346-51.
  29. Opioid receptors and inhibition of dopamine-sensitive adenylate cyclase in slices of rat brain regions receiving a dense dopaminergic input. Heijna MH, Bakker JM, Hogenboom F, Mulder AH, Schoffelmeer AN. Eur J Pharmacol. 1992 Dec 15;229(2-3):197-202.